Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promising therapeutic potential for treating metabolic dysfunction-associated steatohepatitis (MASH).
- MASH is a progressive liver disease with significant treatment challenges.
- GLP-1 RAs may offer a novel approach to managing MASH in adults.
- The efficacy of GLP-1 RAs was evaluated through a meta-analysis of randomized controlled trials.
Simplified